Acidic tumor microenvironment downregulates hMLH1 but does not diminish 5-fluorouracil chemosensitivity

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 747-748, Issue , 2013, Pages 19-27

  Iwaizumi, Moriya ^a   Tseng Rogenski, Stephanie ^a   Carethers, John M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

5 Fluorouracil; Acidic tumor microenvironment; Cell death; Chemotherapy; Colon cancer; DNA mismatch repair

Indexed keywords

ADENINE; FLUOROURACIL; GUANINE; METHYL CPG BINDING PROTEIN; PROTEIN MBD4; PROTEIN MLH1; PROTEIN MUTL; PROTEIN MUTLALPHA; PROTEIN MUTS; PROTEIN MUTSALPHA; PROTEIN MUTSBETA; THYMINE DNA GLYCOSYLASE; UNCLASSIFIED DRUG;

ARTICLE; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG RESISTANCE; EXCISION REPAIR; HUMAN; HUMAN CELL; IN VITRO STUDY; MISMATCH REPAIR; PH; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENINE; ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; BASE PAIRING; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DNA MISMATCH REPAIR; DNA REPAIR; DNA, NEOPLASM; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FLOXURIDINE; FLUOROURACIL; GUANINE; HUMANS; HYDROGEN-ION CONCENTRATION; MUTS HOMOLOG 2 PROTEIN; NEOPLASM PROTEINS; NUCLEAR PROTEINS; NUCLEIC ACID CONFORMATION; TUMOR MICROENVIRONMENT;

EID: 84879113403     PISSN: 00275107     EISSN: 09218262     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2013.04.006     Document Type: Article

References (59)

1. Boland C.R., Sinicrope F.A., Brenner D.E., Carethers J.M. Colorectal cancer prevention and treatment. Gastroenterology 2000, 118:S115-S128.
2. Laurie J.A., Moertel C.G., Fleming T.R., Wieand H.S., Leigh J.E., Rubin J., McCormack G.W., Gerstner J.B., Krook J.E., Malliard J., et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J. Clin. Oncol. 1989, 7:1447-1456.
3. Moertel C.G., Fleming T.R., Macdonald J.S., Haller D.G., Laurie J.A., Goodman P.J., Ungerleider J.S., Emerson W.A., Tormey D.C., Glick J.H., et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med. 1990, 322:352-358.
4. Moertel C.G., Fleming T.R., Macdonald J.S., Haller D.G., Laurie J.A., Tangen C.M., Ungerleider J.S., Emerson W.A., Tormey D.C., Glick J.H., Veeder M.H., Mailliard J.A. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann. Intern. Med. 1995, 122:321-326.
5. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group in Cancer. J Clin Oncol 1998, 16:301-308.
6. Carethers J.M., Chung H., Tajima A. Mismatch repair competency predicts 5-fluorouracil effectiveness on patient survival. Falk Symp. 2007, 158:72-84.
7. Carethers J.M., Smith E.J., Behling C.A., Nguyen L., Tajima A., Doctolero R.T., Cabrera B.L., Goel A., Arnold C.A., Miyai K., Boland C.R. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 2004, 126:394-401.
8. Jover R., Zapater P., Castells A., Llor X., Andreu M., Cubiella J., Balaguer F., Sempere L., Xicola R.M., Bujanda L., Rene J.M., Clofent J., Bessa X., Morillas J.D., Nicolas-Perez D., Pons E., Paya A., Alenda C. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur. J. Cancer 2009, 45:365-373.
9. Ribic C.M., Sargent D.J., Moore M.J., Thibodeau S.N., French A.J., Goldberg R.M., Hamilton S.R., Laurent-Puig P., Gryfe R., Shepherd L.E., Tu D., Redston M., Gallinger S. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 2003, 349:247-257.
10. Sargent D.J., Marsoni S., Monges G., Thibodeau S.N., Labianca R., Hamilton S.R., French A.J., Kabat B., Foster N.R., Torri V., Ribic C., Grothey A., Moore M., Zaniboni A., Seitz J.F., Sinicrope F., Gallinger S. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J. Clin. Oncol. 2010, 28:3219-3226.
11. Marsischky G.T., Kolodner R.D. Biochemical characterization of the interaction between the Saccharomyces cerevisiae MSH2-MSH6 complex and mispaired bases in DNA. J. Biol. Chem. 1999, 274:26668-26682.
12. Acharya S., Wilson T., Gradia S., Kane M.F., Guerrette S., Marsischky G.T., Kolodner R., Fishel R. hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:13629-13634.
13. Blackwell L.J., Bjornson K.P., Modrich P. DNA-dependent activation of the hMutSalpha ATPase. J. Biol. Chem. 1998, 273:32049-32054.
14. de Wind N., Dekker M., Claij N., Jansen L., van Klink Y., Radman M., Riggins G., van der Valk M., van't Wout K., te Riele H. HNPCC-like cancer predisposition in mice through simultaneous loss of Msh3 and Msh6 mismatch-repair protein functions. Nat. Genet. 1999, 23:359-362.
15. Genschel J., Littman S.J., Drummond J.T., Modrich P. Isolation of MutSbeta from human cells and comparison of the mismatch repair specificities of MutSbeta and MutSalpha. J. Biol. Chem. 1998, 273:19895-19901.
16. Habraken Y., Sung P., Prakash L., Prakash S. Binding of insertion/deletion DNA mismatches by the heterodimer of yeast mismatch repair proteins MSH2 and MSH3. Curr. Biol. 1996, 6:1185-1187.
17. Johnson R.E., Kovvali G.K., Prakash L., Prakash S. Requirement of the yeast MSH3 and MSH6 genes for MSH2-dependent genomic stability. J. Biol. Chem. 1996, 271:7285-7288.
18. Kuraguchi M., Yang K., Wong E., Avdievich E., Fan K., Kolodner R.D., Lipkin M., Brown A.M., Kucherlapati R., Edelmann W. The distinct spectra of tumor-associated Apc mutations in mismatch repair-deficient Apc1638N mice define the roles of MSH3 and MSH6 in DNA repair and intestinal tumorigenesis. Cancer Res. 2001, 61:7934-7942.
19. Umar A., Risinger J.I., Glaab W.E., Tindall K.R., Barrett J.C., Kunkel T.A. Functional overlap in mismatch repair by human MSH3 and MSH6. Genetics 1998, 148:1637-1646.
20. Duckett D.R., Drummond J.T., Murchie A.I., Reardon J.T., Sancar A., Lilley D.M., Modrich P. Human MutSalpha recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine, or the cisplatin-d(GpG) adduct. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:6443-6447.
21. Fischer F., Baerenfaller K., Jiricny J. 5-Fluorouracil is efficiently removed from DNA by the base excision and mismatch repair systems. Gastroenterology 2007, 133:1858-1868.
22. Meyers M., Wagner M.W., Mazurek A., Schmutte C., Fishel R., Boothman D.A. DNA mismatch repair-dependent response to fluoropyrimidine-generated damage. J. Biol. Chem. 2005, 280:5516-5526.
23. Tajima A., Hess M.T., Cabrera B.L., Kolodner R.D., Carethers J.M. The mismatch repair complex hMutS alpha recognizes 5-fluorouracil-modified DNA: implications for chemosensitivity and resistance. Gastroenterology 2004, 127:1678-1684.
24. Tajima A., Iwaizumi M., Tseng-Rogenski S., Cabrera B.L., Carethers J.M. Both hMutSalpha and hMutSss DNA mismatch repair complexes participate in 5-fluorouracil cytotoxicity. PLoS ONE 2011, 6:e28117.
25. Iwaizumi M., Tseng-Rogenski S., Carethers J.M. DNA mismatch repair proficiency executing 5-fluorouracil cytotoxicity in colorectal cancer cells. Cancer Biol. Ther. 2011, 12:756-764.
26. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin. Radiat. Oncol. 2004, 14:198-206.
27. Tredan O., Galmarini C.M., Patel K., Tannock I.F. Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst. 2007, 99:1441-1454.
28. Bindra R.S., Glazer P.M. Genetic instability and the tumor microenvironment: towards the concept of microenvironment-induced mutagenesis. Mutat. Res. 2005, 569:75-85.
29. Seo Y., Kinsella T.J. Essential role of DNA base excision repair on survival in an acidic tumor microenvironment. Cancer Res. 2009, 69:7285-7293.
30. Kunz C., Focke F., Saito Y., Schuermann D., Lettieri T., Selfridge J., Schar P. Base excision by thymine DNA glycosylase mediates DNA-directed cytotoxicity of 5-fluorouracil. PLoS Biol. 2009, 7:e91.
31. Sansom O.J., Zabkiewicz J., Bishop S.M., Guy J., Bird A., Clarke A.R. MBD4 deficiency reduces the apoptotic response to DNA-damaging agents in the murine small intestine. Oncogene 2003, 22:7130-7136.
32. Busco G., Cardone R.A., Greco M.R., Bellizzi A., Colella M., Antelmi E., Mancini M.T., Dell'Aquila M.E., Casavola V., Paradiso A., Reshkin S.J. NHE1 promotes invadopodial ECM proteolysis through acidification of the peri-invadopodial space. FASEB J. 2010, 24:3903-3915.
33. Gallagher F.A., Kettunen M.I., Day S.E., Hu D.E., Ardenkjaer-Larsen J.H., Zandt R., Jensen P.R., Karlsson M., Golman K., Lerche M.H., Brindle K.M. Magnetic resonance imaging of pH in vivo using hyperpolarized 13C-labelled bicarbonate. Nature 2008, 453:940-943.
34. Gillies R.J., Raghunand N., Karczmar G.S., Bhujwalla Z.M. MRI of the tumor microenvironment. J. Magn. Reson. Imaging 2002, 16:430-450.
35. Stuwe L., Muller M., Fabian A., Waning J., Mally S., Noel J., Schwab A., Stock C. pH dependence of melanoma cell migration: protons extruded by NHE1 dominate protons of the bulk solution. J. Physiol. 2007, 585:351-360.
36. Webb B.A., Chimenti M., Jacobson M.P., Barber D.L. Dysregulated pH: a perfect storm for cancer progression. Nat. Rev. Cancer 2011, 11:671-677.
37. Gordon J.W., Scangos G.A., Plotkin D.J., Barbosa J.A., Ruddle F.H. Genetic transformation of mouse embryos by microinjection of purified DNA. Proc. Natl. Acad. Sci. U.S.A. 1980, 77:7380-7384.
38. Perucho M., Hanahan D., Wigler M. Genetic and physical linkage of exogenous sequences in transformed cells. Cell 1980, 22:309-317.
39. Bindra R.S., Schaffer P.J., Meng A., Woo J., Maseide K., Roth M.E., Lizardi P., Hedley D.W., Bristow R.G., Glazer P.M. Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol. Cell. Biol. 2004, 24:8504-8518.
40. Koshiji M., To K.K., Hammer S., Kumamoto K., Harris A.L., Modrich P., Huang L.E. HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. Mol. Cell 2005, 17:793-803.
41. Mihaylova V.T., Bindra R.S., Yuan J., Campisi D., Narayanan L., Jensen R., Giordano F., Johnson R.S., Rockwell S., Glazer P.M. Decreased expression of the DNA mismatch repair gene Mlh1 under hypoxic stress in mammalian cells. Mol. Cell. Biol. 2003, 23:3265-3273.
42. Yuan J., Narayanan L., Rockwell S., Glazer P.M. Diminished DNA repair and elevated mutagenesis in mammalian cells exposed to hypoxia and low pH. Cancer Res. 2000, 60:4372-4376.
43. Dang C.V., Semenza G.L. Oncogenic alterations of metabolism. Trends Biochem. Sci. 1999, 24:68-72.
44. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
45. Helmlinger G., Yuan F., Dellian M., Jain R.K. Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat. Med. 1997, 3:177-182.
46. Tannock I.F., Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 1989, 49:4373-4384.
47. Santi D.V. Perspective on the design and biochemical pharmacology of inhibitors of thymidylate synthetase. J. Med. Chem. 1980, 23:103-111.
48. Carethers J.M., Chauhan D.P., Fink D., Nebel S., Bresalier R.S., Howell S.B., Boland C.R. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 1999, 117:123-131.
49. Sowers L.C., Eritja R., Kaplan B., Goodman M.F., Fazakerly G.V. Equilibrium between a wobble and ionized base pair formed between fluorouracil and guanine in DNA as studied by proton and fluorine NMR. J. Biol. Chem. 1988, 263:14794-14801.
50. Hardeland U., Bentele M., Jiricny J., Schar P. The versatile thymine DNA-glycosylase: a comparative characterization of the human, Drosophila and fission yeast orthologs. Nucleic Acids Res. 2003, 31:2261-2271.
51. Petronzelli F., Riccio A., Markham G.D., Seeholzer S.H., Stoerker J., Genuardi M., Yeung A.T., Matsumoto Y., Bellacosa A. Biphasic kinetics of the human DNA repair protein MED1 (MBD4), a mismatch-specific DNA N-glycosylase. J. Biol. Chem. 2000, 275:32422-32429.
52. Hewish M., Lord C.J., Martin S.A., Cunningham D., Ashworth A. Mismatch repair deficient colorectal cancer in the era of personalized treatment. Nat. Rev. Clin. Oncol. 2010, 7:197-208.
53. Li L.S., Morales J.C., Veigl M., Sedwick D., Greer S., Meyers M., Wagner M., Fishel R., Boothman D.A. DNA mismatch repair (MMR)-dependent 5-fluorouracil cytotoxicity and the potential for new therapeutic targets. Br. J. Pharmacol. 2009, 158:679-692.
54. Adamson A.W., Beardsley D.I., Kim W.J., Gao Y., Baskaran R., Brown K.D. Methylator-induced, mismatch repair-dependent G2 arrest is activated through Chk1 and Chk2. Mol. Biol. Cell 2005, 16:1513-1526.
55. Wang Y., Qin J. MSH2 and ATR form a signaling module and regulate two branches of the damage response to DNA methylation. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:15387-15392.
56. Lin D.P., Wang Y., Scherer S.J., Clark A.B., Yang K., Avdievich E., Jin B., Werling U., Parris T., Kurihara N., Umar A., Kucherlapati R., Lipkin M., Kunkel T.A., Edelmann W. An Msh2 point mutation uncouples DNA mismatch repair and apoptosis. Cancer Res. 2004, 64:517-522.
57. Yang G., Scherer S.J., Shell S.S., Yang K., Kim M., Lipkin M., Kucherlapati R., Kolodner R.D., Edelmann W. Dominant effects of an Msh6 missense mutation on DNA repair and cancer susceptibility. Cancer Cell 2004, 6:139-150.
58. Takahashi M., Koi M., Balaguer F., Boland C.R., Goel A. MSH3 mediates sensitization of colorectal cancer cells to cisplatin, oxaliplatin, and a poly(ADP-ribose) polymerase inhibitor. J. Biol. Chem. 2011, 286:12157-12165.
59. Zhao J., Jain A., Iyer R.R., Modrich P.L., Vasquez K.M. Mismatch repair and nucleotide excision repair proteins cooperate in the recognition of DNA interstrand crosslinks. Nucleic Acids Res. 2009, 37:4420-4429.